Phentermine-topiramate sold as Qsymia is the combination of an anorexant and an anti-seizure medication.
This combination of agents is associated with an 8% greater weight loss than placebo among adults with obesity.
Phentermine-topiramate associated with reduced weight circumference by approximately 11 cm, decreases systolic blood pressure by 3 mmHg and reduced low density lipoprotein cholesterol by approximately 6% among adults with obesity.
In patients with type two diabetes, the combination of drugs achieved in mean weight loss of 9.4% and the hemoglobin A1c reduction of 1.6% at 12 months compared with placebo.
Long term phentermine-topiramate can achieve and sustain a 10% weight reduction.
Common adverse events associated with phentetemine – topiramate include 14 to 20% paresthesia, 14 and 19% dry mouth, 15 to 16% constipation and 7 to 9% dysguesia.
Topiramate is associated with the increased congenital fetal oral cleft malformations, and is contraindicated during pregnancy.